Advanced Cell Technology revails in cloning patent dispute.Advanced Cell Technology, Inc. (Worcester, MA) said judgment has been awarded in its favor in a patent interference with Infigen, Inc. (Deforest, WI) involving three key animal patents exclusively licensed by ACT from the University of Massachusetts The system includes UMass Amherst, UMass Boston, UMass Dartmouth (affiliated with Cape Cod Community College), UMass Lowell, and the UMass Medical School. It also has an online school called UMassOnline. . The Board of Patent Appeals and Interferences The Board of Patent Appeals and Interferences (BPAI) is a body of the United States Patent and Trademark Office (USPTO), which decides issues of patentability. If an applicant for an invention cannot convince a patent examiner that they are entitled to their claims, then the of the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property issued the judgment on March 18, 2003. The proceeding involved a challenge initiated by Infigen of United States Patents 5,945,577, 6,215,041, and 6,235,969 assigned to the University of Massachusetts and licensed exclusively to ACT. The disputed patents cover the use of any proliferating somatic cell for the cloning of non-human animals. ACT's patented cloning methods have practical application in the cloning of high-valued animals and for the introduction of genetic modifications into animals for a wide array of agricultural, animal science, companion animal, and human medical applications. ACT has licensed its cloning patents to Cyagra, Inc., of Worcester, Massachusetts, for agricultural applications, PPL Therapeutics, Limited, of Roslin, Midlothian, Scotland and Immerge im·merge intr.v. im·merged, im·merg·ing, im·merg·es To submerge or disappear in or as if in a liquid. [Latin immergere; see immerse. BioTherapeutics, Inc., of Charlestown, Massachusetts, for xenotransplantation xen·o·trans·plan·ta·tion n. The surgical transfer of cells, tissues, or especially whole organs from one species to another. xenotransplantation applications, GTC GTC See: Good 'til cancelled order GTC See good-till-canceled order (GTC). Biotherapeutics, Inc. (Nasdaq: GTCB) of Framingham, Massachusetts, for the production of biopharmaceuticals in milk, and Genetic Savings and Clone of Sausalito, California, for the production of companion animals. The Patent and Trademark Office held that all of the claims of the interfering Infigen patent application were unpatentable because Infigen presented all of these claims more than one year after the ACT patent issued. ACT's President and C.E.O., Michael D. West Dr. Michael D. West is an entrepreneurial scientist and visionary [1] [2] [3] [4] who has led progress in anti-aging and biotechnology. He is CEO of BioTime, Inc. , Ph.D., stated: "We have felt strongly that our technology is unique, and we are very pleased with the Patent Office's decision, which confirms the value of ACT's intellectual property." Advanced Cell Technology is a biotechnology company focused on discovering and commercializing the applications of cloning technology in human medicine and animal science. Advanced Cell Technology, Inc. +1-508-756-1212 www.advancedcell.com |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion